These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6091394)

  • 41. [Epidemiological studies on subacute myelo-optico neuropathy (SMON) in the town of Yubara, Japan. 3].
    Aoyama H; Oira M; Ota T; Yoshioka S; Yoshida T
    Nihon Eiseigaku Zasshi; 1970 Dec; 25(5):468-71. PubMed ID: 4251106
    [No Abstract]   [Full Text] [Related]  

  • 42. Introductory review of subacute myeolo-optico-neuropathy (SMON) and its studies done by the SMON Research Commission.
    Kono R
    Jpn J Med Sci Biol; 1975; 28 Suppl():1-21. PubMed ID: 136534
    [No Abstract]   [Full Text] [Related]  

  • 43. Copper deficiency myeloneuropathy: a clue to clioquinol-induced subacute myelo-optic neuropathy?
    Schaumburg H; Herskovitz S
    Neurology; 2008 Aug; 71(9):622-3. PubMed ID: 18725588
    [No Abstract]   [Full Text] [Related]  

  • 44. Superoxide dismutase as a target of clioquinol-induced neurotoxicity.
    Kawamura K; Kuroda Y; Sogo M; Fujimoto M; Inui T; Mitsui T
    Biochem Biophys Res Commun; 2014 Sep; 452(1):181-5. PubMed ID: 24755073
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Loss-of-function polymorphisms in NQO1 are not associated with the development of subacute myelo-optico-neuropathy.
    Matsumoto H; Sasai H; Kawamoto N; Katsuyama M; Minamiyama M; Kuru S; Fukao T; Ohnishi H;
    Mol Genet Genomic Med; 2024 Jun; 12(6):e2470. PubMed ID: 38860482
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Entero-Vioform and organic neurologic disease.
    Med Lett Drugs Ther; 1971 Jun; 13(12):51-2. PubMed ID: 4326942
    [No Abstract]   [Full Text] [Related]  

  • 47. Subacute myelo-optico-neuropathy (SMON) and clioquinol: -A response to doubts about clioquinol causation theory-.
    Shigematsu I
    Jpn J Med Sci Biol; 1975; 28 Suppl():35-55. PubMed ID: 136540
    [No Abstract]   [Full Text] [Related]  

  • 48. Myelopathy following clioquinol.
    Korczyn AD; Kuritzky A; Bechar M
    Harefuah; 1977 May; 92(10):456-8. PubMed ID: 142039
    [No Abstract]   [Full Text] [Related]  

  • 49. Epidemiological approach to SMON (subacute myelo-optico-neuropathy).
    Shigematsu I; Yanagawa H; Yamamoto S; Nakae K
    Jpn J Med Sci Biol; 1975; 28 Suppl():23-33. PubMed ID: 136539
    [No Abstract]   [Full Text] [Related]  

  • 50. [Prospective study on the side-effects of the clioquinol preparation mexaform with special reference to subacute myelo-optic neuropathy].
    Bezjak B; Breintenfeld V; Schönwald S; Car V; Puskarić-Hamel N; Vrancić J; Hotujac L
    Lijec Vjesn; 1974 Sep; 96(9):553-6. PubMed ID: 4281043
    [No Abstract]   [Full Text] [Related]  

  • 51. [Spinal anesthesia for a patient with long-term SMON].
    Yuasa H; Higashizawa T; Shiokawa Y; Tanaka T; Koga Y
    Masui; 1999 Jan; 48(1):79-80. PubMed ID: 10036897
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Severe myelopathy, peripheral neuropathy and optic neuritis appearing during treatment with chloroiodoquin (clioquinol)].
    Castaiggne P; Rondot P; Lenoel Y; Ribadeau Dumas JL; Autret A
    Therapie; 1973; 28(2):393-400. PubMed ID: 4358276
    [No Abstract]   [Full Text] [Related]  

  • 53. Is there SMON in India?
    Wadia NH
    Neurol India; 1973 Sep; 21(3):95-103. PubMed ID: 4274127
    [No Abstract]   [Full Text] [Related]  

  • 54. [Evaluation of neurological symptoms related to hip fracture in a 29-year longitudinal study of subacute myelo-optic-neuropathy (SMON)].
    Konagaya M; Kuru S; Konagaya Y
    Nihon Ronen Igakkai Zasshi; 2010; 47(5):445-51. PubMed ID: 21116089
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of neurotoxicity of clioquinol (Enterovioform) by visual evoked potentials. A preliminary communication.
    Bhasin DK; Raina R; Mehta SK; Arora MM
    Indian J Gastroenterol; 1985 Jul; 4(3):165-6. PubMed ID: 3160659
    [No Abstract]   [Full Text] [Related]  

  • 56. Clioquinol-zinc chelate: a candidate causative agent of subacute myelo-optic neuropathy.
    Arbiser JL; Kraeft SK; van Leeuwen R; Hurwitz SJ; Selig M; Dickersin GR; Flint A; Byers HR; Chen LB
    Mol Med; 1998 Oct; 4(10):665-70. PubMed ID: 9848083
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Activated T cells in the peripheral blood of patients with subacute myelo-optico-neuropathy (SMON)].
    Matsuda M; Miyagi K; Yanagisawa N; Tsukada N
    Arerugi; 1994 Mar; 43(3):515-20. PubMed ID: 8198461
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of metal-containing drugs taken simultaneously with clioquinol upon clinical features of SMON.
    Okada H; Aoki K; Ohno Y; Kitazawa S; Ohtani M
    J Toxicol Sci; 1984 Nov; 9(4):327-41. PubMed ID: 6241266
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Abnormal activity of polymodal receptors induced by clioquinol (5-chloro-7-iodo-8-hydroxyquinoline).
    Kumazawa T; Mizumura K
    Brain Res; 1984 Sep; 310(1):185-8. PubMed ID: 6236872
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Analysis of the effects of chinoform on subacute myelo-optico-neuropathy (SMON)--application of linear regression analysis by logistic transformation].
    Inoue N; Kuroiwa Y; Ikeda M; Yasukouchi T
    Rinsho Shinkeigaku; 1974 Oct; 14(10):769-73. PubMed ID: 4282713
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.